在绝大多数国产CAR-T企业苦于商业化挣扎之际,率先出海的传奇生物(LEGN.NS)业绩快要“上岸”了。 传奇生物的CAR-T药物合作方强生于当地时间1月21日公布的财报显示,Carvykti(西达基奥仑赛)在2025年实现收入18.88亿美元,较上年同期(9.63亿美元)增长95.9%。 西达基奥仑赛是一款用于治疗复发或难治性多发性骨髓瘤的细胞疗法。2022年2月,这款药在美国获批上市,成为...
Source Link在绝大多数国产CAR-T企业苦于商业化挣扎之际,率先出海的传奇生物(LEGN.NS)业绩快要“上岸”了。 传奇生物的CAR-T药物合作方强生于当地时间1月21日公布的财报显示,Carvykti(西达基奥仑赛)在2025年实现收入18.88亿美元,较上年同期(9.63亿美元)增长95.9%。 西达基奥仑赛是一款用于治疗复发或难治性多发性骨髓瘤的细胞疗法。2022年2月,这款药在美国获批上市,成为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.